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Musculoskeletal Pathology
Detection and Localization of PrPSc in the Skeletal
Muscle of Patients with Variant, Iatrogenic, and
Sporadic Forms of Creutzfeldt-Jakob Disease
Alexander H. Peden, Diane L. Ritchie,
Mark W. Head, and James W. Ironside
From the National Creutzfeldt-Jakob Disease Surveillance Unit
and Division of Pathology, School of Molecular and Clinical
Medicine, University of Edinburgh, Western General Hospital,
Edinburgh, United Kingdom
Variant Creutzfeldt-Jakob disease (vCJD) differs from
other human prion diseases in that the pathogenic
prion protein PrPSc can be detected to a greater extent
at extraneuronal sites throughout the body, princi-
pally within lymphoid tissues. However, a recent
study using a high-sensitivity Western blotting tech-
nique revealed low levels of PrPSc in skeletal muscle
from a quarter of Swiss patients with sporadic CJD
(sCJD). This posed the question of whether PrPSc in
muscle could also be detected in vCJD, sCJD, and
iatrogenic (iCJD) patients from other populations.
Therefore, we have used the same high-sensitivity
Western blotting technique, in combination with par-
affin-embedded tissue blotting, to screen for PrPSc in
muscle tissue specimens taken at autopsy from 49 CJD
patients in the United Kingdom. These techniques
identified muscle PrPSc in 8 of 17 vCJD, 7 of 26 sCJD,
and 2 of 5 iCJD patients. Paraffin-embedded tissue
blotting analysis showed PrPSc in skeletal muscle in
localized anatomical structures that had the mor-
phological and immunohistochemical characteristics
of nerve fibers. The detection of PrPSc in muscle tis-
sue from all forms of CJD indicates the possible
presence of infectivity in these tissues, suggesting
important implications for assessing the potential
risk of iatrogenic spread via contaminated surgical
instruments. (Am J Pathol 2006, 168:927–935; DOI:
10.2353/ajpath.2006.050788)
Creutzfeldt-Jakob disease (CJD) is a member of the hu-
man prion diseases or transmissible spongiform enceph-
alopathies, a group of fatal degenerative diseases of the
central nervous system (CNS). A key event in the patho-
genesis of prion diseases is the conversion of the cellular
prion protein PrPC to the abnormal disease-associated
form PrPSc. According to the prion hypothesis, PrPSc is the
principle or sole component of the infectious agent, and the
accumulation of PrPSc within the CNS has been proposed to
be the primary event leading to neurodegeneration.1
Prion diseases occur in idiopathic, inherited, and ac-
quired forms. The most common human prion disease is
sporadic CJD (sCJD), which occurs worldwide with a
frequency of approximately one per million of the popu-
lation per annum.2–4 The cause of this disease is un-
known, although a random stochastic event resulting in a
conversion of PrPC to PrPSc and the subsequent propa-
gation of this process is one possibility.5 CJD can also be
acquired by iatrogenic transmission (iCJD) as a result of
certain neurosurgical procedures, dura mater or corneal
transplantation, and through treatment with cadaveric hu-
man growth hormone as reviewed by Brown and col-
leagues.6 A novel acquired human prion disease, variant
Creutzfeldt-Jakob disease (vCJD), is thought to result
from oral exposure to the bovine spongiform encepha-
lopathy agent.7 vCJD is clearly distinct from other forms
of CJD in its neurological, neuropathological, and bio-
chemical phenotype.
PrPSc differs from PrPC in its relative resistance to
proteases and is often referred to as PrPres after partial
proteolytic degradation. Although PrPSc accumulation
occurs primarily in the brain, PrPres has also been de-
tected in the peripheral tissues of CJD patients.8–10 This
is particularly the case for vCJD in which PrPres is readily
detected in the lymphoid tissues including, spleen, tonsil,
lymph nodes, and Peyer’s patches using standard West-
ern blotting and immunohistochemistry techniques.9,10 In
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contrast, in sCJD PrPres accumulation (and by implication
infectivity) was thought to be primarily confined to the
CNS.9–11 However, earlier transmission studies had dem-
onstrated infectivity in extraneural tissues, including
spleen, lung, liver, and kidney, but not skeletal muscle or
peripheral nerve.12 Also, there was always the possibility
that the detection of low levels of PrPres in peripheral
organs in all forms of CJD may be limited by the sensi-
tivity of the assays used. This was highlighted recently by
Glatzel and colleagues8 who were able to detect PrPres in
autopsy specimens of spleen and muscle in a proportion
of sCJD patients in Switzerland using a high-sensitivity
Western blotting technique involving selective precipita-
tion of PrPres with sodium phosphotungstic acid (NaPTA).
The detection of PrPres in the muscle of Swiss sCJD
patients presents the worrying prospect of the transmis-
sion of prion infection via instruments used in ordinary
surgical procedures. Indeed, a collaborative case control
study performed on sCJD patients in Europe showed that
a past history of surgery was a risk factor.13 The study by
Glatzel and colleagues8 requires confirmation in sCJD
patients from other populations. The study was purely
biochemical in nature and did not investigate the local-
ization of PrPres within the muscle tissue. Lastly, the work
of Glatzel and colleagues8 raises the question of whether
PrPres is present in the muscle of patients with other forms
of CJD, most notably vCJD, where the extent of periph-
eral PrPres tends to be greater.9,10 Because of the oral
route of infection in vCJD and the presumed long incu-
bation period,14 infectious prions may be present in the
peripheral tissues for a considerable period of time be-
fore the onset of clinical symptoms. For this reason vCJD
may pose an increased risk for the iatrogenic transmis-
sion of the disease. This risk had been highlighted re-
cently by two cases of the secondary transmission of
vCJD infection by blood transfusion from donors who only
developed vCJD after donation.15,16
To address the above issues, we have used the same
high-sensitivity NaPTA precipitation/Western blotting
technique to screen skeletal and heart muscle samples
from UK patients with vCJD, iCJD, as well as sCJD. We
show that PrPres is indeed present in a significant pro-
portion of autopsy skeletal muscle samples taken from
vCJD, iCJD, and sCJD patients, and we go on to use the
paraffin-embedded tissue (PET) blotting technique to de-
termine the localization of PrPres within human muscle
tissue.
Materials and Methods
Cases and Tissue Specimens
Seventeen vCJD patients, twenty-six sCJD cases, and
five iCJD cases (associated with human growth hormone
therapy) were analyzed in this study by a combination of
Western blotting and PET blotting. Twelve cases of clin-
ically suspected CJD that were given an alternative final
pathological diagnosis were included as negative con-
trols because they would be expected to lack PrPres in
the brain and peripheral tissues. Cases were selected for
this study on the basis of the availability of fixed and
frozen tissue specimens retained at autopsy and the
existence of consent for tissue retention and research
use. Ethical approval for the acquisition and use of au-
topsy material for research on transmissible spongiform
encephalopathies in the National CJD Surveillance Unit
brain bank is covered by LREC 2000/4/157 (Prof. J.W.
Ironside). All autopsy cases were of UK origin. The brain
from each case had previously been examined histolog-
ically and biochemically, and a definite diagnosis of vari-
ant, sporadic, or iatrogenic CJD (or non-CJD) had been
reached by established criteria.17,18 The protease-resis-
tant prion protein (PrPres) isotype found in brain was
classified as type 1, 2A, or 2B as previously described
according to the nomenclature of Parchi and col-
leagues.19–22 The polymorphic status of codon 129 of the
prion protein gene PRNP of each case was determined
by restriction fragment length polymorphism.22
Western Blot Analysis
The skeletal muscle taken at autopsy was from quadri-
ceps, sternomastoid, or intercostal muscles. Frozen skel-
etal and cardiac muscle tissues from CJD and non-CJD
control patients were analyzed by the high-sensitivity
Western blotting protocol described by Glatzel and col-
leagues8 and Wadsworth and colleagues10 previously,
with a few modifications. Briefly, 10% w/v extracts were
made of 65- to 100-mg samples of tissue by homogeniz-
ing in an appropriate volume of ice-cold 2% sarkosyl/
phosphate-buffered saline (PBS), pH 7.4, using the Fast-
Prep instrument (Qbiogene, Cambridge, UK). The
samples were then cleared by centrifugation at 5200  g
for 5 minutes at 4°C. Samples (0.5 ml) of the cleared
lysates were diluted with a further 0.5 ml of 2% sarkosyl/
PBS and incubated for 10 minutes at 37°C. Benzonase
(Sigma, Poole, UK) and MgCl2 were added at final con-
centrations of 50 U/ml and 1 mmol/L, respectively, and
incubation at 37°C was continued for a further 30 min-
utes. Eighty-one l of a stock solution of 4% w/v NaPTA
and 170 mmol/L MgCl2, pH 7.4, was added (final con-
centration of NaPTA, 0.3% w/v), and precipitation was
allowed to occur for 30 minutes at 37°C. The samples
were centrifuged at 20,800  g for 30 minutes at 37°C.
The resultant supernatant was discarded and the pellets
were resuspended in 20 l of 0.1% w/v sarkosyl in PBS,
pH 7.4, and digested with 50 g/ml proteinase K for 30
minutes. Digestion was terminated by the addition of 1
mmol/L PefaBloc SC (Roche, Lewes, UK).
Electrophoresis was performed using the NuPAGE
Novex gel system (Invitrogen, Paisley, UK). Before elec-
trophoresis, NuPAGE LDS sample buffer was added to
each of the samples to a final concentration of 1. The
samples were boiled for 10 minutes and separated on
10% Bis-Tris NuPAGE gels. The separated proteins were
then transferred onto immunoblot polyvinylidene difluo-
ride membrane (Bio-Rad, Hertfordshire, UK). For immu-
nodetection, the anti-PrP monoclonal antibody 3F4 (Da-
koCytomation, Cambridgeshire, UK) was used at a final
concentration of 50 ng/ml IgG for 1 hour. Horseradish
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peroxidase-conjugated anti-mouse IgG F(ab)2 fragment
(Amersham Biosciences, Amersham, UK) was used at a
dilution of 1 in 40,000 for 1 hour. The detection reagent
used was SuperSignal West fempto maximum sensitivity
substrate (Pierce, Rockford, IL). The immunoblots were
exposed to HyperFilm ECL (Amersham Biosciences) for
periods of 10 seconds to 30 minutes. The molecular
weight of PrPres was estimated by reference to IgG-bind-
ing MagicMark XP Western protein standards (Invitro-
gen), and standard PrPres samples from vCJD brain were
run on all blots throughout the study. These standards
were prepared by PK digestion using the conventional
method described previously.18,23
Criteria for Assigning Positives
Frozen muscle samples from nine non-CJD neurological
patients were available for use as negative controls in the
Western blots in this study. As a positive control in these
experiments, 10 l of 1% w/v vCJD (type MM2B) brain
homogenate was diluted into 0.5 ml of 10% w/v muscle
tissue homogenate from one of the non-CJD control pa-
tients. This spiked muscle homogenate was then diluted
with a further 0.5 ml of 2% sarkosyl as described above.
Precipitation with NaPTA and PK digestion were per-
formed as described for the test samples. Samples of
CJD patient muscle tissue were assessed by comparison
with positive and negative control samples run either on
the same gel or on a separate gel run in parallel at the
same time using exactly the same conditions.
Our laboratory and others have shown tissue-specific
effects on the apparent glycosylation profile of PrPres that
can lead to an underrepresentation of one of the three
characteristic bands observed on the Western blots.9,10
Therefore, the following criteria were established before
interpreting the results. A positive result was assigned if
three or at least two bands were observed to co-migrate
with any of the corresponding PrPres bands in the positive
control and no bands or smears were seen in the lane
containing non-CJD control muscle sample, after maxi-
mum exposure to HyperFilm ECL. A negative result was
assigned if less than two bands were present in the
correct region in the lane containing the test sample on a
blot where the positive control was detected.
Immunohistochemistry and PET Blotting
The localization of PrPres in paraffin sections of cardiac
and skeletal muscles was investigated using the highly
sensitive PET blot method.24,25 To establish the cellular
location of PrPres deposits, conventional immunohisto-
chemistry was performed to compare the localization of a
number of cellular markers with the distribution of PrPres.
Serial 5-m sections from both formalin-fixed and perio-
date-lysine paraformaldehyde-fixed, formic acid-treated
sections were mounted on Superfrost plus slides (VWR,
Poole, UK) for immunohistochemistry and on 0.45-m
nitrocellulose membrane for PET blot analysis. Slides and
membranes were incubated overnight at 55°C before
use.
PET Blotting
PET blot analysis was performed as described by us
previously24 using a modified version of the method
of Schulz-Schaeffer and colleagues25 Briefly, sections
mounted on nitrocellulose were dewaxed before an over-
night digestion in 25 g/ml of proteinase K. Membranes
were washed in Tris-buffered saline containing 0.1%
Tween-20 before treatment with 3 mol/L guanidine iso-
thiocyanate for 10 minutes. After a further wash the mem-
branes were blocked with casein and incubated for 2
hours with 3F4 antibody (1:500 dilution). Labeling was
completed using a Vectastain ABC-AmP detection sys-
tem (Vector Laboratories, Peterborough, UK) and visual-
ized using the nitro blue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate chromogen system. Sections from
sCJD brain were included with each PET blot run as a
positive control for the primary antibody. Labeling was
observed and photographed using a stereomicroscope.
Immunohistochemistry
Investigations on the cellular location of PrPres in muscle
tissue were performed using antibodies raised against
neurofilament protein, neuron-specific enolase, synapto-
physin, and S-100 protein (all from DakoCytomation).
Before immunolabeling sections were dewaxed and im-
mersed in picric acid to remove formalin pigment. After
washing in water all sections were pretreated by micro-
waving in 10 mmol/L citrate buffer, pH 6.0, for 15 minutes.
Immunolabeling was then completed using the Envision
Plus HRP kit (DakoCytomation) for the anti-neuron-spe-
cific enolase antibody of Vectastain Elite ABC kit (Vector
Laboratories) for the other antibodies. Staining was visu-
alized using diaminobenzidine.
Results
Western Blotting
We applied our modified Western blotting protocol to
assess muscle tissue samples from a total of 49 CJD
patients and 9 non-CJD neurological disease patients.
Patients with vCJD
Seventeen patients with a definite diagnosis of vCJD
(numbered V1 to V17) were analyzed for PrPres in their
skeletal muscle, and eight positives were identified (Fig-
ure 1) using the criteria described above. The immuno-
blot for patient V9 shows that samples taken from these
patients contained varying amounts of PrPres (Figure 1,
top). Samples assigned as positive from the remaining
seven vCJD patients are shown together in the bottom
panel of Figure 1. Only a proportion of samples taken
from these patients contained detectable PrPres (Table
1), suggesting that PrPres has a heterogeneous distribu-
tion within the muscle tissue. The samples that were
positive contained PrPres at levels approximately equal to
the positive control, which contained 100 g of vCJD
brain homogenate. Because each sample is the NaPTA
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precipitate from 50 mg of wet weight of tissue, we esti-
mate that the levels of PrPres in these positive muscle
samples were 1:500 that of vCJD brain.
Patients with sCJD
Using this same Western blotting technique, 6 of 26
patients with definite sCJD were identified as being pos-
itive for skeletal muscle PrPres (Figure 2). Two of these
patients, S7 and S10, were also shown to be positive by
PET blotting (see below). Patient S10 had a particularly
strong signal for PrPres in all three samples taken. Inter-
estingly, the unglycosylated PrPres fragment was under-
represented in the muscle from patient S10 when com-
pared with PrPres from the CNS (spinal cord) of this
patient (Figure 2). The bands identified as being PrPres in
the other positive samples were often diffuse. However,
the signals obtained were distinct from the results ob-
tained from an analysis of skeletal muscle from nine
patients with non-CJD neurological disease. A total of 22
muscle samples were analyzed from this cohort of nine
patients, and no bands were observed even on extended
Figure 1. Western blots of vCJD patient muscle samples positive for PrPres.
Samples of muscle homogenate equivalent to 50 mg wet weight of tissue
were precipitated with NaPTA, digested with PK, and immunoblotted with
anti-PrP antibody 3F4 as the primary reagent, as described in the Materials
and Methods section. Top: A typical immunoblot for assessing CJD patient
muscle for the presence of PrPres. Two muscle samples from the vCJD patient
V9 are compared with muscle from non-CJD neurological disease control
patient, one of which has been spiked with 100 g of vCJD brain homoge-
nate. The bands that we infer to be PrPres are indicated with asterisks. These
precipitates were run in parallel with vCJD brain standards before () and
after () PK digestion. The molecular weights in kd of the MagicMark XP
standards (M) are indicated on the left. Bottom: A composite image taken
from six separate immunoblots showing muscle samples from the seven
other vCJD patients assigned as positive by Western blotting, aligned with
vCJD brain standard (100 g). The gaps in the upper bar indicate where the
separate immunoblots have been aligned.
Table 1. Pathological, Genetic, and Clinical Profiles of CJD Patients with Muscle Shown to Be Positive for PrPres by Western
Blotting (WB) and PET Blotting
Case WB PET Codon 129 Brain PrPres type
vCJD patients (17 analyzed)
V2 (1/4) (0/1) MM 2B
V5 (3/7) (0/1) MM 2B
V6 (1/2) (0/1) MM 2B
V8 (1/7) (0/1) MM 2B
V9 (2/4) (0/1) MM 2B
V12 (1/13) (0/1) MM 2B
V13 (1/3) (0/1) MM 2B
sCJD patients (26 analyzed)
S7 (1/2) (1/1) MV 2A (1)
S8 (1/2) (0/1) MM 1  2A
S10 (3/3) (1/1) MV 1
S11 (2/7) (0/1) MM 1
S14 (0/3) (1/1) MV 2A
S24 (1/2) (0/1) MM 1
S25 (1/2) (0/1) MV 2A
iCJD patients (5 analyzed)
I4 (4/5) (0/1) VV 2A
I5 (0/3) (1/1) MV 2A
The number of samples tested (no. positive for PrPSc/total) is indicated in parentheses. The positive scores are indicated in bold type.
Figure 2. Western blots of sCJD patient muscle samples positive for PrPres.
Samples of muscle from six patients assigned as positive are compared with
muscle from a non-CJD neurological control patient and vCJD control brain
homogenate (100 g) diluted into non-CJD control muscle homogenate.
Two of the patients, S7 and S10, were also positive by PET blotting (see
Figure 4). As in Figure 1, the bands that we infer to be PrPres are indicated
with asterisks. The gaps in the upper bar indicate where separate blots have
been aligned. For comparison, the PrPres signal obtained from spinal cord
from patient S10 after NaPTA precipitation and Western blotting is shown in
the final lane.
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exposures, as exemplified by the control samples shown
in Figures 1, 2, and 3.
Patients with iCJD
Frozen skeletal muscle tissue from five patients with
human growth hormone-associated iCJD were available
for analysis by Western blotting. One of these patients
(I4) was positive for PrPres for four of five muscle samples
taken (Figure 3). Interestingly, the unglycosylated frag-
ment was below the limit of detection in all samples taken.
However, using the criteria described above we were
able to assign a positive result as two visible bands
co-migrated with bands corresponding to the di- and
monoglycosylated forms of PrPres in the spiked positive
control, which was the NaPTA precipitate from 100 g of
vCJD (PrPres type MM2B) brain extract diluted in 50 mg of
non-CJD control muscle homogenate (Figure 3). As
shown in Figure 3, PrPres obtained after NaPTA precipi-
tation and PK digestion in the spiked positive control
(vCJD, spike) consistently had a higher apparent molec-
ular weight than PrPres from vCJD extract prepared and
PK-digested without prior NaPTA precipitation (vCJD,).
As shown previously NaPTA causes this effect when
applied to PrPSc before proteolysis by altering the PK
cleavage site, resulting in the generation of larger PrPres
fragments.10 Because the spiked positive control repli-
cates the conditions used for the NaPTA precipitation
and PK digestion of the test samples, the bands obtained
for this control should be used for evaluating bands ob-
tained in the control samples. The absence of a positive
score for one of the five samples from patient I4 (Figure 3)
again implies a heterogeneous distribution of PrPres in the
muscle tissue.
Localization of PrPres in Muscle Tissue
PET Blot Analysis of CJD Patients
To investigate the muscle tissue heterogeneity we
have used PET blotting to localize PrPSc in sections of
muscle tissue.24 Fixed tissue from 17 vCJD, 22 sCJD,
three iCJD, and 11 non-CJD cases in our cohort were
available for PET blot analysis using the anti-PrP antibody
3F4. Of the 22 sCJD patients analyzed, three (S7, S10,
Figure 4. PET blot and immunohistochemical analysis of PrP in sections of
sCJD skeletal muscle. A: PET blot preparation showing labeling of PrPres in
longitudinal nerve fibers within a muscle sample from sCJD patient S10. B:
Paraffin section adjacent to A showing the presence of a nerve fiber bundle
in the site of the PrPres labeling (H&E). C: Paraffin section adjacent to A
showing a similar pattern of staining in large diameter axons to the positive
labeling for PrPres after immunocytochemistry for neurofilament protein. D:
PET blot preparation showing labeling of PrPres in an oblique cross-section
of large diameter axons within a muscle sample from sCJD patient S7.
Original magnifications: 200 (A–C); 400 (D).
Figure 3. Western blots of iCJD patient muscle samples positive for PrPres.
Three samples of muscle from an iCJD patient (I4) are compared with 100 g
of vCJD brain homogenate diluted in non-CJD control muscle homogenate,
NaPTA precipitated, and digested with PK (vCJD spike). Also shown are
samples of vCJD brain homogenate before () and after () digestion with
PK (50 g and 200 g, respectively) without NaPTA precipitation. Non-
spiked, non-CJD muscle homogenate, digested with PK, is shown in the last
lane as a negative control. As noted previously10 there is a slight upward shift
in the mobility of PrPres after NaPTA precipitation (vCJD spike lane).
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and S14) were found to be positive for PrPres (examples
shown in Figure 4, A and D). Two of these patients (S7
and S10) had previously been found to be positive by
Western blotting (Figure 1). Therefore, this analysis
brought the total number of sCJD patients positive for
skeletal muscle PrPres to seven (of 26). PET blotting also
showed PrPres immunoreactivity in another of the three
iCJD patients analyzed. None of the 17 vCJD patients
analyzed were positive using this technique, and no la-
beling was observed in the 11 non-CJD control patients
(data not shown). For all four positive samples, PrPres
labeling occurred in a linear pattern with a distribution
and morphology consistent with nerve fibers (see below).
No labeling of muscle fibers, motor end plates, or muscle
spindles was observed.
Immunohistochemistry
To further investigate the localization of PrPres at higher
resolution within the muscle tissue, further immunohisto-
chemistry analysis was performed on adjacent skeletal
muscle sections from the four cases shown to be positive
by PET blotting. Antibodies to S100 protein were used to
label Schwann cells, and antibodies to synaptophysin,
neurofilament protein, and neuron-specific enolase were
used to label axons in nerve fibers within the tissue (Fig-
ure 4C). In muscle sections from all three sCJD patients
(S7, S10, and S14) and the iCJD patient (I5) the pattern of
immunoreactivity on these sections closely resembled
the pattern seen for PrPres on PET blots of adjacent
sections (Figure 4, A and D), with most co-localization
seen in small nerve fiber bundles.
Pathological, Genetic, and Clinical Profiles of
CJD Patients with PrPres-Positive Skeletal
Muscle
The pathological, genetic, and clinical data for the pa-
tients positive for muscle PrPres were analyzed against
the data for all of the CJD patients in this study. The data
on the PRNP codon 129 genotype and brain PrPres iso-
type combinations and duration of illness of the vCJD,
sCJD, and iCJD patients identified as positive for PrPres in
muscle are shown in Table 1. The clinical durations of all
of the sCJD and vCJD patients in this study are pre-
sented as box and whisker plots in Figure 5.
The positive sCJD patients (indicated by asterisks)
tended to have longer clinical durations; five of the seven
patients identified as positive had durations of illness
longer than 4 months, the median for this data set (Figure
5) and for sCJD in general.26 Two of the positive sCJD
patients were outliers with clinical durations of 21 and 54
months. This may suggest a positive correlation between
the duration of illness and the detection of PrPres in mus-
cle, although the numbers of patients analyzed in this
study is insufficient for firm conclusions to be drawn. No
such correlation was seen within the vCJD group (Figure
5). However, vCJD patients on average have significantly
longer clinical durations (median, 14 months14), and a
greater proportion of vCJD patients (8 of 17) tested pos-
itive for PrPres than sCJD patients (7 of 26).
Our study was unable to confirm the suggestion of
Glatzel and colleagues8 of a bias toward atypical PRNP
gene codon 129 genotype and PrPres isotype combina-
tions in cases that tested positive for PrPres in muscle.
Two of the seven muscle PrPres-positive patients had the
most common PrPres subtype MM1, whereas three had
the rarer subtype MV2A (Table 1).20,22 The two growth
hormone-associated iatrogenic CJD patients identified
as positive for muscle PrPres both had clinical durations
(7 and 9 months) and codon 129/PrPres isotype combi-
nations (VV2 and MV2) that are typical for this form of the
disease.
Analysis of Heart Muscle from CJD Patients for
PrPres
Heart muscle was available for analysis from 12 sCJD
patients in our cohort, including three of the seven sCJD
patients that were positive for PrPres in skeletal muscle.
Similarly, heart muscle from 12 vCJD patients from our
cohort including four that had tested positive for skeletal
muscle PrPres were tested by PET blotting and Western
blotting. Cardiac muscle from one iCJD patient (I5) was
also tested. We obtained no positives using either tech-
nique. Our results are therefore in agreement with previ-
ous analyses of heart tissue from CJD patients by West-
ern blotting.9,10
Figure 5. Clinical durations of sCJD and vCJD patients positive for PrPres in
muscle. The distribution of the clinical durations (in months) of the 17 vCJD
patients and the 26 sCJD patients in this study are represented by box and
whisker diagrams. Patients with durations of illness greater than [75th per-
centile  (1.5  the interquartile range)] were defined as outliers and are
indicated by filled circles. The positions of the vCJD and sCJD patients
positive for PrPres in muscle within these distributions are indicated with
asterisks.
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Discussion
In their recent article Glatzel and colleagues8 were the
first to demonstrate PrPres (the proteinase K-resistant
core fragment of PrPSc) in the muscle and spleen of
approximately a third of sCJD patients. In this study we
take these findings further by showing that 1) PrPres ac-
cumulates in the skeletal muscle of acquired as well as
idiopathic CJD, including vCJD and growth hormone-
associated iCJD; 2) the presence of PrPres in sCJD mus-
cle is not exclusive to just the one population and is not
the result of an etiology unique to Swiss sCJD patients; 3)
the presence of abnormal pathogenic PrPSc in skeletal
muscle from sCJD patients can be confirmed using two
different techniques; 4) PrPres can be localized to struc-
tures within skeletal muscle that resemble nerves; and 5)
PrPres is not detected in heart muscle from CJD patients
using the same set of techniques. In support of these
results, PrPres has recently been reported (in abstract
form) in skeletal muscle from an Italian patient with
vCJD.27 Together, these findings contrast markedly with
previous studies of CJD patients by our laboratory and
others, concluding that PrPres was primarily undetectable
in tissues outside the CNS and PNS (and additionally the
lymphoid system in vCJD).9,10 Our ability to now detect
PrPres in muscle is probably due to increases in the
sensitivity of both our PET blot technique24 and our West-
ern blotting method; in the latter case the main improve-
ments were a more thorough disruption of the tissue and
the introduction of the NaPTA precipitation step.
Heterogeneous Distribution of PrPres in Skeletal
Muscle
The results from our Western blot and PET blot analyses
showed that PrPres had a heterogeneous distribution
within the muscle tissue from these patients, which was
also observed in muscles of Swiss sCJD patients8 and
sheep naturally infected with scrapie.28 This heterogene-
ity makes estimating the levels of PrPres in muscle diffi-
cult. However, in the positive muscle samples the signals
obtained for 50 mg of muscle tissue were equivalent to
0.1 mg of vCJD brain (cerebral cortex) used as a positive
control (Figures 1 to 3). This suggests that the PrPres
levels in positive muscle samples were 1/500 that of
vCJD cerebral cortex.
The heterogeneity and paucity of PrPres within the skel-
etal muscle tissue of CJD patients may explain why no
positive PET blots were obtained for 17 vCJD patients,
even though eight of these patients were positive by
Western blot. Separate samples of muscle tissue taken
from the cases were analyzed using these three tech-
niques. Clearly, the size, location and numbers of sam-
ples taken from a given specimen from a human patient
will have a direct bearing on the likelihood of a positive
result. This underscores the need to take multiple sam-
ples and use the most highly sensitive techniques avail-
able when assessing peripheral tissues for the presence
of PrPres.
Glatzel and colleagues8 proposed a positive correla-
tion between the duration of disease and the detection of
PrPres in muscle. In our study the sCJD patients positive
for muscle PrPres tended to have clinical durations above
the median average for this group. No such correlation
was seen within our cohort of vCJD patients. However,
vCJD overall is characterized by a longer clinical dura-
tion, and it is noteworthy that a greater proportion of vCJD
patients were positive for PrPres in muscle than sCJD
patients. This suggests that a longer clinical duration may
increase the likelihood of detecting PrPres in muscle.
However, we were unable to see a bias toward less
common combinations of PRNP codon 129 genotype and
brain PrPres subtype for the patients positive for PrPres in
muscle.
Biochemical Profile of PrPres in Muscle
A clear distinction was seen between muscle and CNS
PrPres in terms of the glycosylation pattern. In the positive
sCJD and iCJD cases, the fastest migrating unglycosy-
lated fragment was underrepresented in the muscle com-
pared with PrPres from the CNS. Tissue-specific effects
on the glycoform ratio of PrPres have been observed
previously by our laboratory and others.9,10 Interestingly,
a predominance of the di- and monoglycosylated bands
is also seen in muscle PrPres from the case of concurrent
sCJD and inclusion body myositis reported by Kovacs
and colleagues.29 In the positive vCJD patients, the di-
glycosylated fragment of PrPres did not always predomi-
nate in contrast to PrPres in brain and other tissues in
vCJD patients.9,10 This suggests that the relationship
between agent strain and the PrPres glycosylation pattern
is not straightforward and is influenced by the tissue in
which PrPres has accumulated.
Localization of PrPres to Musculoskeletal Nerve
Fibers
With the PET blot method, muscle sections positive for
PrPres from the three sCJD patients and the iCJD patient
all showed patterns of PrPres deposition consistent with
nerve fibers, with no apparent labeling of skeletal muscle
fibers, motor end plates, or muscle spindles. In all four
patients, this was supported by immunohistochemistry
analysis of muscle sections using antibodies to label
Schwann cells and axons. Although the PET blot tech-
nique may not be able to demonstrate all PrPres in these
tissues, it clearly indicates that the most abundant PrPres
deposition is in the intramuscular nerve fibers.
Cardiac muscle differs from skeletal muscle in its
structure, physiology, and innervation; one or more of
these factors may underlie the absence of detectable
PrPres in the heart samples from 25 patients with vCJD,
sCJD, or iCJD examined by Western blotting or PET
blotting. However, a recent report has suggested that a
dilated cardiomyopathy in a patient with sCJD may have
been induced by the presence of abnormal prion protein,
leaving open the question of whether PrPSc is present in
the heart in very rare cases of CJD.30
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Our study is the first to demonstrate PrPSc in muscu-
loskeletal nerves from CJD patients. Previous analyses of
PrPSc deposition in the peripheral nervous system of CJD
patients gave mixed results. Primate transmission studies
failed to identify prion infectivity in the peripheral nerve of
sCJD patients.12 Western blot analysis has showed
PrPres in the trigeminal and dorsal root ganglia, but not
peripheral or sciatic nerve in both sCJD and vCJD pa-
tients.9,10 However, PrPres has now been detected in the
stellate and celiac ganglia of vCJD but not sCJD pa-
tients.31 This supports a role for gut-associated sympa-
thetic neurons in the propagation and centripetal spread
of vCJD prions in humans after oral contamination. Most
recently Ishida and colleagues32 have reported the im-
munohistochemical detection of PrPSc deposits in the
peripheral nerves of dural graft-associated iCJD patients,
suggesting centrifugal spread of prions from the CNS to
the periphery. However, a centrifugal spread may not be
relevant in vCJD or iCJD cases after growth hormone
therapy because a peripheral route of primary infection is
likely to apply in both groups. It remains to be seen
whether the invasion of muscle tissue by PrPSc occurs at
an early stage in the progression of the disease or indeed
whether it occurs in presymptomatic individuals. In this
context, it should be noted that no PrPres was detected by
NaPTA precipitation/Western blot in the muscle tissue
taken at autopsy from a patient with preclinical vCJD
infection in the spleen as reported previously.16
Comparison with Animal Prion Disease Models
Muscle PrPres was more readily detected in mouse33 and
hamster34 prion disease models compared with our
study of human CJD patients. In contrast to studies of
muscle from sheep intracerebrally challenged with
scrapie,28 we could not detect an association of PrPres
with muscle spindles. Furthermore, PrPres was not found
to be associated with muscle fibers in human CJD pa-
tients in contrast to muscles from hamsters orally infected
with 263K scrapie.34 The greater and more widespread
deposition of PrPres in the scrapie hamster and scrapie
sheep models may be a consequence of increased in-
fection pressure and/or infectivity titer in these disease
models compared with human prion diseases. The infec-
tivity titers of 108 to 109 ID50/g determined for brain in
the mouse33 and hamster35 scrapie models are much
greater than the estimate of 105 ID50/g for CJD brain,
12
even when we take into account the inevitable species
barrier when human CJD tissues are bioassayed. For
these reasons experimental ovine and rodent disease
models may exaggerate the extent of PrPres in the pe-
ripheral tissue when compared with natural disease
states. Our findings caution against an overreliance on
these models when assessing human disease.
Public Health Implications
There is a strong correlation between the presence of
PrPSc and infectivity in prion diseases. Hence these stud-
ies would suggest that prion infectivity is indeed present
in the skeletal muscle tissue from all forms of CJD, both
acquired and sporadic, albeit at levels two orders of
magnitude lower than those found in the CNS. The pres-
ence of PrPSc in skeletal muscle suggests that the poten-
tial risk of iatrogenic spread may be a cause for concern
for a range of surgical procedures, although further in-
vestigation is required to allow a full risk assessment.
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